Evolus, Inc. (EOLS)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$7.47+4.62%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $493M
- Forward P/E
- 25.5
- 52-week range
- $3.86 – $9.31
- 52-week change
- +14.06%
- EPS (trailing)
- −$0.53
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $297M (+11.61%)
- Net income
- −$51.6M
- Operating margin
- −11.0%
- Diluted EPS
- −$0.80
- Free cash flow
- −$45.7M
From the company’s annual report on SEC EDGAR.
About Evolus, Inc.
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Headquarters: Newport Beach, United States · 353 employees · evolus.com